NEW YORK, NY / ACCESSWIRE / May 19, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
AbbVie Inc. (NYSE:ABBV)
Class Period: April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline: June 6, 2022
The ABBV lawsuit alleges that AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
Learn about your recoverable losses in ABBV: https://www.kleinstocklaw.com/pslra-1/abbvie-inc-loss-submission-form-2?id=27480&from=1
Natera, Inc. (NASDAQ:NTRA)
This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive.
Lead Plaintiff Deadline: June 27, 2022
The complaint alleges that throughout the class period Natera, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company's screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.
Learn about your recoverable losses in NTRA: https://www.kleinstocklaw.com/pslra-1/natera-inc-loss-submission-form?id=27480&from=1
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Class Period: December 30, 2019 - April 22, 2022
Lead Plaintiff Deadline: July 12, 2022
During the class period, Axsome Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in AXSM: https://www.kleinstocklaw.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?id=27480&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE : The Klein Law Firm